Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial

Abstract Patients with schizophrenia have exceedingly high rates of metabolic comorbidity including type 2 diabetes and lose 15–20 years of life due to cardiovascular diseases, with early accrual of cardiometabolic disease. In this study, thirty overweight or obese (Body Mass Index (BMI) > 25) pa...

Full description

Bibliographic Details
Main Authors: Sri Mahavir Agarwal, Roshni Panda, Kenya A. Costa-Dookhan, Nicole E. MacKenzie, Quinn Casuccio Treen, Fernando Caravaggio, Eyesha Hashim, General Leung, Anish Kirpalani, Kelly Matheson, Araba F. Chintoh, Caroline K. Kramer, Aristotle N. Voineskos, Ariel Graff-Guerrero, Gary J. Remington, Margaret K. Hahn
Format: Article
Language:English
Published: Nature Publishing Group 2021-04-01
Series:Translational Psychiatry
Online Access:https://doi.org/10.1038/s41398-021-01338-2

Internet

https://doi.org/10.1038/s41398-021-01338-2

Similar Items